AstraZeneca Launches Exploratory Study to Predict Onset of ILD in NSCLC Patients on Imfinzi

AstraZeneca said on June 4 that it initiated an exploratory study in Japan earlier this month in patients with non-small cell lung cancer (NSCLC) who received treatment with the anti-PD-L1 antibody Imfinzi (durvalumab) in a bid to build a model...read more